| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/21/2002 | CA2070788C Process for producing spagyric essences from plants |
| 05/16/2002 | WO2002039117A1 Methods for the treatment of cellular proliferative disorders |
| 05/16/2002 | WO2002038775A2 METHODS FOR PRODUCING AND PURIFYING RECOMBINANT α-L-IDURONIDASE |
| 05/16/2002 | WO2002038646A2 Novel polyesters, method for producing the same and depot medicaments produced from these polyesters |
| 05/16/2002 | WO2002038577A2 Extended release erythromycin derivatives |
| 05/16/2002 | WO2002038530A1 Carboxylic acid type lipid |
| 05/16/2002 | WO2002038266A1 Apparatus and method for producing antimicrobial silver solution |
| 05/16/2002 | WO2002038208A2 Device and method for the cessation of smoking |
| 05/16/2002 | WO2002038186A1 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides |
| 05/16/2002 | WO2002038185A2 Injectable sustained release delivery system with loperamide |
| 05/16/2002 | WO2002038184A1 Oral pharmaceutical composition containing a block copolymer |
| 05/16/2002 | WO2002038183A2 Delivery devices |
| 05/16/2002 | WO2002038182A1 Asthma treatment |
| 05/16/2002 | WO2002038175A1 Vaccines with enhanced immune response and methods for their preparation |
| 05/16/2002 | WO2002038171A2 METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE |
| 05/16/2002 | WO2002038170A2 Stabilized inteferon compositions |
| 05/16/2002 | WO2002038168A2 Use of selectin-binding active ingredients for the treatment of inflammatory and tumoral diseases |
| 05/16/2002 | WO2002038161A1 Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
| 05/16/2002 | WO2002038154A1 Novel medicament compositions based on tiotropium salts and on salmeterol salts |
| 05/16/2002 | WO2002038149A1 Remedies for keratoconjunctival diseases containing farnesyl acetate as the active ingredient |
| 05/16/2002 | WO2002038147A1 Granular drug preparations containing branched amino acids and process for producing the same |
| 05/16/2002 | WO2002038144A2 The use of tiagabine for treatment of diabetic neuropathy and migraine |
| 05/16/2002 | WO2002038139A1 Pharmaceutical preparation of percutaneous absorption type |
| 05/16/2002 | WO2002038138A2 Primary packaging for transdermal therapeutic systems or medical plasters |
| 05/16/2002 | WO2002038137A2 Skin friendly active ingredient plaster for transdermal administration of rubefacient active ingredients |
| 05/16/2002 | WO2002038136A2 Skin friendly active ingredient plaster for transdermal administration of etheric oils |
| 05/16/2002 | WO2002038135A2 Flexible barrier film for a support material for medical applications |
| 05/16/2002 | WO2002038134A2 Multilayered supporting construction for plaster systems containing an active ingredient |
| 05/16/2002 | WO2002038133A2 Compositions containing hydrolytically unstable compounds |
| 05/16/2002 | WO2002038132A2 Soft capsules comprising a starch mixture having a reduced branching degree |
| 05/16/2002 | WO2002038131A2 Process |
| 05/16/2002 | WO2002038130A1 Chamber for in vivo screening of angiogenesis and tumor growth modulating compounds |
| 05/16/2002 | WO2002038129A2 Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
| 05/16/2002 | WO2002038128A1 Method for preparing microsome dispersion |
| 05/16/2002 | WO2002038127A2 Particle formation methods and their products |
| 05/16/2002 | WO2002038126A2 A process for production of particles for pharmaceutical compositions having increased bioavailability |
| 05/16/2002 | WO2002038077A2 L-histidine in ophthalmic solutions |
| 05/16/2002 | WO2002037977A1 Creamy based processed dairy product containing gelatine |
| 05/16/2002 | WO2002020026A3 Treatment of drug resistant organisms with nitric oxide |
| 05/16/2002 | WO2002017905A3 Treatment of burns |
| 05/16/2002 | WO2002017892A3 Water-dispersible encapsulated sterols |
| 05/16/2002 | WO2002013762A3 Improved solid pharmaceutical dosage formulation of hydrophobic drugs |
| 05/16/2002 | WO2002009671A3 Microemulsion and micelle systems for solubilizing drugs |
| 05/16/2002 | WO2002003871A8 Use of a liquid medicament in surgical high pressure liquid jet devices |
| 05/16/2002 | WO2002000680A3 Cationic steroid derivatives for gene delivery |
| 05/16/2002 | WO2002000218A3 Methods of treating neutrophil-related diseases with topical anesthetics |
| 05/16/2002 | WO2001098335A3 Transgenic algae for delivering antigens to an animal |
| 05/16/2002 | WO2001097851A3 Compositions and methods to improve the oral absorption of antimicrobial agents |
| 05/16/2002 | WO2001095890A3 Oral pharmaceutical compositions containing terbinafine |
| 05/16/2002 | WO2001094001A3 Novel microcapsules |
| 05/16/2002 | WO2001091703A3 Low emulsifier multiple emulsions |
| 05/16/2002 | WO2001089514A3 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent |
| 05/16/2002 | WO2001089511A3 Superficial therapeutic system containing o-acetylsalicylic acid, for treating skin pain |
| 05/16/2002 | WO2001089446B1 Device for the coating of granulates and seeds |
| 05/16/2002 | WO2001087289A3 Propofol for treatment of sepsis |
| 05/16/2002 | WO2001087270A3 Vaccine composition, method of preparing the same, and method of vaccinating vertebrates |
| 05/16/2002 | WO2001076597A3 A method of administering an antitumour compound using a polymer-camptothecin conjugate |
| 05/16/2002 | WO2001074347A8 Method for reducing adverse effects of a weight loss regimen |
| 05/16/2002 | WO2001070663A3 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 05/16/2002 | WO2001068745A3 Liquid crystalline polymers |
| 05/16/2002 | WO2001068144A3 Biodegradable immunomodulatory formulations and methods for use thereof |
| 05/16/2002 | WO2001068143A3 Immunomodulatory formulations and methods for use thereof |
| 05/16/2002 | WO2001041739A3 Liposomes |
| 05/16/2002 | WO2001039747A3 Cassette-shaped constructional units in a rotary printing machine |
| 05/16/2002 | WO2001032125A3 Apparatus and process for preparing crystalline particles |
| 05/16/2002 | US20020059049 System and method for rapidly customizing design, manufacture and/or selection of biomedical devices |
| 05/16/2002 | US20020058926 Synchronising of animal oestrus and intra vaginal devices useful therein |
| 05/16/2002 | US20020058906 Microprocessor controlled ambulatory medical apparatus with hand held communication device |
| 05/16/2002 | US20020058795 Preferential particles for use in the transfer of macromolecules into cells; for use in gene therapy |
| 05/16/2002 | US20020058714 Base material for dry direct tableting comprising low-substituted hydroxypropyl cellulose |
| 05/16/2002 | US20020058705 For use in therapy of hypercholesterolemia, as anti- ischemic and/or anti-thrombotic agent, as antiplatelet agent, or as agent against gastric ulcers induced by compounds, agents or drugs |
| 05/16/2002 | US20020058704 Multicomponent compositions containing chitosan and methods of preparing same |
| 05/16/2002 | US20020058674 Used for therapy of conditions associated with mucosal surfaces such as cervical dysphasia and cervical intraepithelial neoplasia |
| 05/16/2002 | US20020058650 Penetration enhancing and irritation reducing systems |
| 05/16/2002 | US20020058647 Preparing a slurry of pamidronic acid in water, combining aqueous sodium hydroxide with slurry to obtain disodium pamidronate; packaging solution in sealed containers to obtain unit dosage |
| 05/16/2002 | US20020058643 Lyophilizate of lipid complex of water insoluble porphyrins |
| 05/16/2002 | US20020058640 Liquid based vaso-occlusive compositions |
| 05/16/2002 | US20020058624 Powder containing physiologically active peptide |
| 05/16/2002 | US20020058622 Water-insoluble or slightly water-soluble polyvalent metal salt (especially zinc) of a water soluble peptide type of physiologically active substance and a biodegradable polymer. |
| 05/16/2002 | US20020058616 Coadministration of a an oral bioavailability-enhancing agent (e.g., a cyclosporin F or ketoconazole) with a drug that exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide) |
| 05/16/2002 | US20020058614 Especially administered by direct injection into the afflicted cartilagenous region or joint. |
| 05/16/2002 | US20020058608 Buffered drug formulations for transdermal electrotransport delivery |
| 05/16/2002 | US20020058601 Low-foaming; good biodegradability; can be used in polymer, antifoaming, biocidal, coating, fertilizer, pharmaceutical, and drilling fluid compositions. |
| 05/16/2002 | US20020058318 Gels for encapsulation of biological materials |
| 05/16/2002 | US20020058101 Elongated structure with a proportion of the length in the c axis to that in the b axis < 2.0 |
| 05/16/2002 | US20020058070 Intimate mixture of a sapid agent, such as a sweetener, and an enhancer, proportion of sapid agent relative to the enhancer is substantially constant and equal in all powder particles. |
| 05/16/2002 | US20020058069 Use of microparticles having a protein and an antibody adsorbed thereon for preparing a pharmaceutical composition for intranasal administration |
| 05/16/2002 | US20020058068 Blend of two or more acrylic-based polymers having differing functionalities so as to modulate the drug solubility in the polymer matrix and the delivery rate of the drug |
| 05/16/2002 | US20020058067 Solid drug delivery system |
| 05/16/2002 | US20020058066 Outer layer portion containing cilostazol, a water-insoluble substance, such as ethyl cellulose, and a hydrophilic hydrogel forming substance, such as hydroxypropyl methyl cellulose. |
| 05/16/2002 | US20020058065 Insoluble drug particle compositions with improved fasted-fed effects |
| 05/16/2002 | US20020058064 Flavored gelatin capsule and method of manufacture |
| 05/16/2002 | US20020058063 Stable pharmaceutical dosage form for paroxetin anhydrate |
| 05/16/2002 | US20020058062 At least 13% glucoside isoflavones and 0.6-1.5 parts 3 soya saponins per 1 part by weight of glucoside isoflavones; treating pre or post menopausal symptoms, breast and prostate cancer, and alcoholism |
| 05/16/2002 | US20020058061 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 05/16/2002 | US20020058060 Liposome for incorporating large amounts of hydrophobic substances |
| 05/16/2002 | US20020058058 Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| 05/16/2002 | US20020058055 Oil-containing biliquid foam dispersed in a salt-containing aqueous phase having a pH of less than about 7, is gelled by a polymeric sulfonic acid, e.g., ammonium acrylamidopropanesulfonic acid-vinylformamide copolymer |
| 05/16/2002 | US20020058050 Treating pain by administering 24 hours opioid formulations exhibiting rapid rise of drug level |
| 05/16/2002 | US20020058049 Stable ophthalmic preparation |